Chronic disease pressure is structural
The World Health Organization states that noncommunicable diseases account for 74% of all deaths globally. Payers cannot solve that with claims management alone; prevention-led engagement has to start earlier.
For Insurers & Payers
Health Insurance Biomarker Testing
MeScreen helps insurers, payers and prevention-led health plan providers add mitochondrial function insight to member wellbeing programmes. The result is a differentiated benefit built around early engagement, cellular energy and long-term health behaviour, not another generic health questionnaire.
Summary: what MeScreen offers payers
MeScreen is a wellness and functional laboratory assessment that can be deployed as a member engagement benefit, prevention programme add-on or partner-branded cellular health screen. It supports at-home collection, secure digital reporting, bulk ordering and optional aggregated insights, while staying clearly outside diagnostic or underwriting decision-making unless separately governed by appropriate clinical and legal frameworks.
Prevention is the battleground for modern health plans
Private medical insurance, health cash plans and employer-funded wellbeing products are under pressure to prove value before a claim happens. Members want useful insight. Employers want engagement. Payers want earlier behaviour change and sharper differentiation. MeScreen gives all three a credible conversation starter: mitochondrial health, cellular resilience and measurable follow-up.
Member engagement remains the weak link
Most health plans already know prevention matters. The operational problem is getting members to act before they are ill. A personalised biological report gives prevention a concrete starting point.
MeScreen is built for non-invasive rollout
Members collect a dried blood spot sample at home, send it for analysis and receive a secure digital report. The process avoids clinic scheduling friction and scales more cleanly across distributed populations.
How MeScreen strengthens payer propositions
Differentiate prevention packages with cellular health insight
Many payer products offer similar benefits: GP access, health checks, mental health support and discounts. MeScreen gives plans a distinctive biological layer that is easy to explain and harder for competitors to copy quickly.
Increase member activation with a personal report
A report about mitochondrial function is more compelling than a generic reminder to exercise. Members can see why energy, sleep, nutrition, recovery and oxidative stress matter, then connect those habits to their own result profile.
Support prevention without making diagnostic claims
MeScreen is positioned as a wellness and functional laboratory assessment. It can support education, behaviour change and programme design without claiming to diagnose, treat or predict individual disease outcomes.
Create a smarter partner channel for employers
Payers serving employer groups can offer MeScreen as a voluntary benefit for leadership teams, high-stress roles or prevention-focused cohorts. The same infrastructure can support bulk ordering, communication packs and retesting cycles.
Best-fit use cases for insurers, payers and health plans
Use case
Target population
Commercial value
Member engagement benefit
Health-conscious members and prevention plan subscribers
Adds a distinctive wellness service that encourages members to interact with the plan before illness
Employer group add-on
Corporate clients investing in wellbeing and retention
Improves B2B plan differentiation and gives HR teams a measurable benefit to communicate
Lifestyle intervention support
Members enrolled in coaching, recovery, nutrition or activity programmes
Creates a baseline and follow-up framework for behaviour-change programmes
White-label prevention product
Payers with branded wellbeing ecosystems
Allows MeScreen to sit inside a broader digital health or prevention proposition
Clear governance: wellness insight, privacy and responsible use
Health data requires discipline. MeScreen should be framed as a wellness assessment for member education and engagement. Individual results belong to the member. Any aggregated reporting, white-label integration, data flow or research use should be scoped before launch, with GDPR, consent and data minimisation designed into the programme from day one.
- Member-facing consent language before testing begins.
- Clear explanation that MeScreen is not a diagnostic test and does not replace medical advice.
- Optional anonymised aggregate reporting for programme-level insight where scale allows.
- Defined exclusion of individual results from employment, underwriting or eligibility decisions unless a separate regulated pathway is agreed.
- Co-branded or white-label communications for selected payer partnerships.
How payer implementation works
- Define the member cohort. Agree whether the first rollout is employer-funded, member-paid, subsidised or included inside a prevention tier.
- Set the engagement objective. Choose the primary aim: differentiation, member activation, lifestyle programme support, leadership health or research-linked insight.
- Design the consent and communication pathway. Align member wording, privacy boundaries, support materials and escalation language.
- Deploy kits and reporting. Members complete at-home collection, laboratory analysis is completed, and secure digital reports are released.
- Review aggregate programme learning. Where appropriate, use anonymised programme data to improve education, follow-up and future rollout design.
Build a prevention product members can feel
If your health plan needs a sharper cellular health proposition, start with a controlled pilot. MeScreen can talk through cohort sizing, white-label options, data governance, member communication and commercial structure.
Book a payer partnership callHealth insurance biomarker testing FAQs
How can insurers use biomarker testing?
Insurers can use biomarker testing as a prevention-led member benefit, an employer-group wellbeing add-on, a lifestyle programme support tool or a white-label wellness product. MeScreen focuses on mitochondrial function and cellular health, not diagnosis.
Can MeScreen reduce insurance claims?
MeScreen should not be presented as a guaranteed claims-reduction tool. Its value is earlier engagement, member education and support for prevention-focused behaviour change. Claims impact would need to be evaluated through a properly designed payer study.
Can MeScreen data be used for underwriting?
The standard MeScreen B2B proposition is for wellness engagement, not underwriting. Any underwriting use would require separate legal, regulatory, clinical and consent frameworks. The responsible default is that individual results remain with the member.
Does MeScreen offer white-label partnerships?
White-label or co-branded partnerships may be available for selected payers, health plans and enterprise partners. The right model depends on volume, data flow, support requirements and compliance boundaries.
Is MeScreen suitable for employer-funded health plans?
Yes. MeScreen can be used as a voluntary add-on for employer groups, especially where the employer is already investing in wellbeing, leadership performance, prevention or retention.
What does the member receive?
The member receives an at-home collection kit, laboratory analysis and a secure digital report explaining their mitochondrial function and related cellular health markers in a practical, education-led format.
Schema-ready structure
- Recommended schema: Service, Organization, BreadcrumbList and FAQPage.
- Primary service name: Health insurance biomarker testing partnership.
- Audience: insurers, payers, health plan leaders, employer benefits platforms and prevention programme owners.
- Service area: United Kingdom.